REG - Immupharma PLC - Corporate Update

ImmuPharmaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251124:nRSX6319Ia&default-theme=true

RNS Number : 6319I  Immupharma PLC  24 November 2025

 

 

24 November 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

 Corporate Update

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announces an update on P140 partnership discussions.

 

In the Corporate Update notification of 23 October 2025, ImmuPharma advised
that it had started to engage with a number of potential partners on P140, and
that the Company's stated objective was to complete a deal by the end of 2025.
 

Potential partners who have expressed an interest in P140 range in size and
scope and include a number of top ten global Pharma companies. A number of
parties have signed Confidential Disclosure Agreements.

 

As would be expected, discussions cover a broad spectrum of subjects including
scientific, technical and commercial aspects of P140 and by their nature these
are, and continue to be, detailed and time consuming.

 

ImmuPharma's objective is to identify "the best fit" partner for P140's
further development and commercialisation and to secure the best possible deal
for ImmuPharma's shareholders.

 

To this end, based on the engagements with potential partners to date, the
Board now expects the completion of any partnership deal to extend beyond the
end of 2025, with our aim being to move to completion of a deal as soon as
practicable in 2026.

 

Further updates will be communicated to the market as and when further
progress has been made, as appropriate.

Financial Update and Outlook

ImmuPharma's financial position remains strong, benefiting from recent R&D
tax credits received; exercise of warrants (as per notifications made on 11
and 17 September 2025) and enhanced receipts under the now completed Lanstead
Capital sharing agreement, which resulted in aggregate receipts of c£2m (a 7%
increase over the original subscription (as detailed in the 13 February 2025
notification) of £1.875m). As a result, the current cash runway now extends
well into Q4 2026. The Company reaffirms it has no intention to raise further
funds and will look to further strengthen its cash position as a result of
deals with potential commercial partners.

 

Tim McCarthy, Chief Executive Officer of ImmuPharma, commented:

"We are very encouraged by the positive response we have received in our
partnering discussions. As a reminder, the advances within our P140 autoimmune
platform represent a paradigm shift in how autoimmune therapies will be
diagnosed and treated and underline the strong scientific foundation and
commercial potential of our technology.

The whole team is dedicated to securing a partnership deal that does justice
to the innovation and clinical potential of P140, valuing a more methodical
approach over speed, so the best outcome for shareholders can be achieved. We
are seeking a partner whose culture and aspirations match those of the Board,
prioritising long-term synergy.

The Company's financial position is now secure into Q4 2026 which provides the
Company with the support and time to advance partnership activities. We look
forward to providing further updates in due course."

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

 

 

 

Notes to Editors

About ImmuPharma PLC

 

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBJBBTMTBTTTA



            Copyright 2019 Regulatory News Service, all rights reserved